MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WEBER, W. W.
Right arrow Articles by COHEN, S. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WEBER, W. W.
Right arrow Articles by COHEN, S. N.

Molecular Pharmacology, Vol 3, 266-273, Copyright © 1967 by the American Society for Pharmacology and Experimental Therapeutics

N-Acetylation of Drugs: Isolation and Properties of an N-Acetyltransferase from Rabbit Liver

WENDELL W. WEBER 1 and SANFORD N. COHEN 1

1 Department of Pharmacology, New York University School of Medicine, New York, New York 10016

The characteristics and kinetic properties of an N-acetyltransferase have been studied in partially purified preparations from rabbit liver. The enzyme catalyzes the acetylation of isonicotinic acid hydrazide, sulfadiazine, sulfamerazine, sulfamethazine, and sulfanilamide. A "ping-pong Bi-Bi" mechanism, which involves the formation of an acetylated enzyme, is proposed for the acetylation of INH from our studies of initial velocity patterns and product inhibition. The possible limitations of the Michaelis constant (Km) as a means of characterizing an enzyme which catalyzes "ping-pong Bi-Bi" reactions or other reactions involving two or more substrates and two or more products are noted.

Note:
ACKNOWLEDGMENTS We wish to thank Dr. B. N. La Du for his advice throughout these studies. This investigation was supported in part by U. S. Public Health Service Grant AM 08577 from the National Institutes of Health.

Submitted on January 9, 1967




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
N. J. Butcher, A. Arulpragasam, and R. F. Minchin
Proteasomal Degradation of N-Acetyltransferase 1 Is Prevented by Acetylation of the Active Site Cysteine: A MECHANISM FOR THE SLOW ACETYLATOR PHENOTYPE AND SUBSTRATE-DEPENDENT DOWN-REGULATION
J. Biol. Chem., May 21, 2004; 279(21): 22131 - 22137.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. W. Hein, C. A. McQueen, D. M. Grant, G. H. Goodfellow, F. F. Kadlubar, and W. W. Weber
Pharmacogenetics of the Arylamine N-Acetyltransferases: A Symposium in Honor of Wendell W. Weber
Drug Metab. Dispos., April 13, 2001; 28(12): 1425 - 1432.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
J. De Angelis, J. Gastel, D. C. Klein, and P. A. Cole
Kinetic Analysis of the Catalytic Mechanism of Serotonin N-Acetyltransferase (EC 2.3.1.87)
J. Biol. Chem., January 30, 1998; 273(5): 3045 - 3050.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1967 by the American Society for Pharmacology and Experimental Therapeutics